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1. Introduction
A pharmaceutical drug is technically obtained or prepared for prophylactic, curative, pallia‐
tive or diagnostic purposes. The final product must meet quality standard, be safe and effec‐
tive. In Brazil, there is a high demand for formulated drugs. This is mainly due to their
lower price compared to manufactured drugs, evidenced by the rapid growth – an increase
of 350% from 1998 to 2010.
Even after the ANVISA’s (Agency National Health Surveillance) establishment of the new
handling standards to be followed by the magistral pharmacies, several serious cases, in‐
cluding death reports, caused by the consumption of formulated drugs have recently be‐
come public [1-5].
Other problems related to this subject occurred in 2004, when deaths caused by manipulated
medicines of low therapeutic index (clonidine and levotiroxine) led ANVISA to modify the
regulation for manipulated medicines. The concentration of each compound was not totally
assured and the contamination by impurities, not included in the original formula, were
present in the final product.
In a previous work, we have also observed the presence of impurities – such as metals - in
different kinds of medicines. The ingestion of metals, even at low levels, can be very harm‐
ful to humans. Besides this, the long-term uptake of some drugs is also risky. This should
require attention and surveillance from the public health-related agencies [6-10].
The  quality  and safety  of  drugs  must  follow the  specifications  described  in  the  official
compendia  -  among them,  the  pharmacopoeias.  Medicines  cannot  contain  impurities  or
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other  substances  that  endanger  the  patient’s  health.  According to  the  second edition  of
the Brazilian Pharmacopoeia National Formulary [1], to ensure safety, efficacy and quali‐
ty of  the handled products it  is  necessary correct  calculations,  exact  measurements,  and
adequate conditions and procedures of  preparation.  The prudent judgment of  the phar‐
macist, who must be a qualified professional for this purpose, is another fundamental as‐
pect.  Additionally,  an appropriate profile  with a proven stability must be sought in the
literature [11-14].
The requirements of sanitary legislation and quality control of raw materials for magistral
solid preparations are:
• raw material: character sensory, solubility, pH determination, melting point, density,
weight and volume; analysis report of manufacturer/supplier;
• raw material of vegetal origin: organoleptic characters, solubility, pH determination,
melting point, density, weight and volume, evaluation of vendor analysis report;
• manipulated product: solid dosage forms: description, appearance and organoleptic char‐
acteristics, determination of average weight
The  legislation  also  determines  that  all  pharmacies  must  perform  analyzes  every  two
months of at least one of the formulas containing drug(s) ≤ 25 mg of drugs. The priority
is  to those that  contain ≤ 5  mg of  drugs.  The legislation establishes special  quality con‐
trol  requirements  for  preparations  of  substances  with  low  therapeutic  index,  like  hor‐
mones,  antibiotics and cytotoxic drugs,  homeopathic products,  and sterile  products.  The
raw materials used in sterile preparations must also be analyzed [15-17].
The Legislation on Good Practices  for  Handling does  not  require  impurity  tests  for  the
raw materials received by the pharmacies. It  is only necessary to check the certificate of
a  qualified  supplier  –  issued  in  accordance  with  methods  described  in  the  pharmaco‐
poeia,  which are  only  suitable  for  the  detection of  some elements  (Ag,  As,  Bi,  Cd,  Hg,
Mo, Pb, Sb, and Sn) [18].
Quality  control  tests  for  the  products  handled do not  include  detection  and quantifica‐
tion  of  impurities.  Moreover,  the  analysis  required  for  formulated  preparations  allow
limited conclusions about the quality of the process, since they do not testify the homo‐
geneity of the active principle directly, but only as to the uniformity of filling of the cap‐
sules.  So,  a  particular  formulation  can  have  the  acceptance  criteria  for  average  mass,
standard deviation and coefficient of variation but not the uniformity of this active con‐
tent in the capsules [19].
Periodic reviews performed every two months for formulated drugs do not statistically have
significant value, so that a reliable conclusion about the quality of formulated drugs can not
be reached [20]. The analysis of thirty batches of 20 mg of Sinvastatin medicine manipulated
in pharmacies of Belo Horizonte, showed that only fourteen of them, met the quality stand‐
ard required by pharmacopeia. Thus, the therapeutic efficacy of 53% of the analyzed prod‐
ucts can not be totally dependable [21].
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In this study, the quality of medicines Omeprazole and Enalapril Maleate from five (5) dif‐
ferent magistral pharmacies was evaluated according to the methodology described in phar‐
macopoeia. The analyses for mass determination, identification of active principle, content,
content uniformity and related compounds were performed.
The target drugs, Omeprazole and Enalapril Maleate, were chosen because of their represen‐
tativeness of consumption and availability of related reference data in the pharmacopoeias.
In order to evaluate the presence and concentration of chemical elements, the technique
used in this study was neutron activation analysis (NAA), applying the k0-standardization
method [23-25]. The neutron activation analysis is a very sensitive and reliable multielemen‐
tal technique, suitable for determination of the elements such as: As, Ba, Br, Ca, Ce, Cl, Co,
Cr, Eu, Fe, Hf, Mg, Mn, Na, Sb, Sc, Sm, Ti and Zn, in different drugs [14]. The technique is
based on the principle that when the material is irradiated by neutrons, some elements with
suitable nuclear characteristics become radioactive isotopes. Thus, the concentration of each
element can be determined by counting the respective radiation emitted by the correspond‐
ing radionuclide [26].
The results described here are part of a wider project which also includes the analyses of
Fluoxetin and Sinvastatin medicines and will be published briefly.
2. Quality control of formulated drugs
2.1. The pharmacopeia
The 5th edition of the Brazilian Pharmacopoeia [27] defines quality control as: "The set of
measures to ensure, at any time, the batch production of medicines and other products that
meet the standards of identity, activity, content, purity, efficacy and safety." According to
Resolution RDC Nº. 67, October 8, 2007 [15], which provides the Technical Regulation estab‐
lishing the Good Handling Practices in Pharmacies (Good Compounding Practices) quality
control of magistral and officinal preparations, is given by the completion of at minimum,
the tests described in Table 1, according to the Brazilian Pharmacopoeia or other Official
Compendium recognized by the National Health Surveillance Agency (ANVISA).
Results of tests must be recorded in the same order of handling, in addition to other relevant
information. The pharmacist must evaluate the results to approve or not the preparation for
dispensing. Each pharmacy is responsible for the quality of magistral preparations that han‐
dles, keeps, transports and dispenses. Raw materials should be checked in its receipt and
moved to quarantine soon after, until the release of the reports of quality control. In the ab‐
sence of pharmacopoeia monograph, the scientific literature should be used as a reference,
and only with the lack of literature, the specification provided by the supplier may be used.
All results must be written and stored [15].
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Preparation Test
Solid Description, appearance, organoleptic characteristics, average mass
Semi-solid Description, appearance, organoleptic characteristics, pH (where applicable), mass
Non-sterile liquid Description, appearance, organoleptic characteristics, pH, mass or volume before filling
Table 1. Tests for quality control of magistral drugs
However, some studies also show that the rule of Good Practices on Handling does not an‐
swer and does not guarantee the quality of compounded drugs [20].
2.2. Analyses performed
The analyses of quality control were performed at the Laboratory for Quality Control of
Chemical Physics Drug, and Cosmetic Sanitizing of the Ezequiel Dias Foundation (FUNED).
The following tests were performed [15,27,28]:
• Aspect;
• Identification ;
• Labeling;
• Content;
• Related compounds;
• Dosage uniformity;
• Unit Change in mass;
The test of aspect is just a visual description of the product to be analyzed, coloration of the
capsule and its content.
The  test  of  identification allows determining the  presence  of  the  active  principle  in  the
product analyzed. It  is  performed through the high performance liquid chromatography
(HPLC) [28].
The analysis of content aims to verify whether the drug has a dose of active ingredient on
the label provided and used to quantify the active ingredient in the product analyzed. This
test is performed according to the pharmacopoeia for each product, and may be performed
in the ultraviolet and visible spectrophotometry, by high performance liquid chromatogra‐
phy, among other methods. The test uses usually ten to twenty capsules and each capsule
analyzed separately, but the "pool" of these. There are limits specified in the monograph,
which should be within the active drug, usually 90 to 110%. Results below the limit can re‐
sult in ineffective therapy and above, intoxication, depending on the drug analized [28].
The analysis of related compounds determines the amount of by-products of synthesis of
the substance and / or its degradation products and / or contaminants from the process of
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obtaining the substance which can be normally found within a specified limit. This test is
done only when specified in the pharmacopoeia.
The variation of the mass allows checking the uniformity of mass between units within a
batch. For products in hard capsules should be weighed individually, twenty units, the con‐
tents of each one should be removed, properly cleaned and reweighed. The mass content of
each capsule is determined by mass difference between the full and the empty capsule. Then
the average mass of the contents can be determined. For hard capsules, the limit of variation
is ± 10% of the mass corresponding to less than 300 mg. If the mass corresponds to 300 mg or
more, the maximum range is ± 7.5%. It cannot be tolerated more than two units outside the
limits specified in the official compendia, but none can be above or below twice the percen‐
tages indicated [27].
The uniformity of dosage units evaluate the uniformity of distribution of active component
units in a single batch can be determined by two methods: mass variation and content uni‐
formity. The mass variation test is only applicable in specific cases. The test for content uni‐
formity is based on the content of each active ingredients in a number of unit doses in order
to determine whether the content is within specified limits, being applicable in all cases [28].
3. Methodology
3.1. High performance liquid chromatography
In this study the identification tests, content, related compounds and content uniformity
was performed by high performance liquid chromatography (HPLC) according to the speci‐
fications of literature [28]. The chromatograph Shimadzu detector was coupled to molecular
absorption spectrophotometry in the ultraviolet-visible Perkin Elmer Lambda 25 model,
Class-VP software. All chemical reference substances (SQR) were purchased from USP (The
United States Pharmacopeia).
To analyze the Enalapril Maleate, L7 C8 column (4.6 mm x 25 cm x 5 mm) was used. Isocratic
elution was performed with a buffer monobasic sodium phosphate pH 2.2 /acetonitrile at a
ratio of 75:25. Solvents and solutions were degassed in ultrasonic bath (Elma Transsonic
Digitals) and filtered through a Millipore membrane of 0.45 micrometers. Chromatography
was performed at 50°C, flow rate of 2 mL.min-1, with injections of 50 µL, detection at 215 nm
and running time of 30 min. The calculations were based on the content of the samples ob‐
tained areas of the areas of the SQR of Enalapril Maleate. For related compounds the content
of diketopiperazine compounds and enalaprilat was also calculated.
For omeprazole, L7 C8 column (4.6 mm x 15 cm x 5 mm) was used. Elution was performed
by mixing two solutions – solution A (6 g of glycine in 1500 mL water, pH 9) and solution B
(acetonitrile and methanol, 85:15 ratio) – as shown in Table 3. Solvents and solutions were
degassed in ultrasonic bath (Elma Transsonic Digitals) and filtered through a Millipore
membrane of 0.45 micrometers. Chromatography was performed with a flow of 1,2
mL.min-1, with injections of 10 µL, detection at 305 nm and running time of 30 min. The cal‐
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culations were based on the content of the samples obtained areas of the areas of the SQR of
omeprazole.
Time (minutes) Solution A (%) Solution B (%) Elution
0 – 20 88 → 40 12 → 60 Linear gradient
20 – 21 40 → 88 60 → 12 Linear gradient
21 – 25 88 12 Isocratic
Table 2. Parameters of elution of the HPLC analysis of Omeprazole
3.1.1. Results and discussion
a. Appearance, Identification and Labeling
Both, Omeprazole and Enalapril Maleate samples, showed similar aspects as their samples:
hard capsule containing white pellets for Omeprazole, and hard capsule containing white
powder varying only the color of the hard capsule used by each pharmacy. All samples,
Omeprazole and Enalapril Maleate, were satisfactory for labeling and identification, con‐
firming that the identity of the material was in accordance with the label from its packaging.
In addition, all labels contain information provided by RDC Resolution Nº 67, October 8,
2007 [15]:
1. Name of the prescriber;
2. Name of the patient;
3. Registration Number of the formulation;
4. Data handling and shelf life;
5. Formulation components and their quantities;
6. Number of units;
7. Dosage;
8. Identification of pharmacy, full address and federal registration;
9. Name and professional register of the responsible person.
b. Related substances (Enalapril Maleate)
The test for related substances is performed only when described in the pharmacopeia of the
compound to be analyzed, or another official compendium regulated by ANVISA [28]. For
the Enalapril Maleate it is specified that no more than 5% of diketopiperazine and enalapri‐
lat can be found in the final product. All samples of Enalapril Maleate were satisfactory for
this analysis and the results are shown in Table 5.
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Pharmacy Enalaprilat (%) Diketopiperazine (%) Enalaprilat +Diketopiperazine (%)
A 0.66 0.82 1.48
B 0.16 0.07 0.23
C 0.53 0.87 1.40
D 0.05 0.001 0.055
E 1.18 2.77 3.95
Table 3. Content of related compounds of Enalapril Maleate
c. Content
The reference values for the content of both drugs should not be less than 90% nor exceed
110% of the declared value, 10 mg and 20 mg for omeprazole and enalapril, respectively.
The results for content of active ingredient are described in Table 6.
It can be observed that four from the five samples of omeprazole were unsatisfactory; two of
them with content above the permissible and the other two with the content below. For the
samples of enalapril, two were unsatisfactory, one exceeding the limit and the other with
recommended content lower than expected, as showed in Table 6.
Pharmacy Omeprazole (10 mg/caps) Enalapril Maleate (20 mg/caps)
A (11.3 ± 0.4) mg/caps or112.7% declared
(18.5 ± 0.2) mg/caps or
92.6% of declared
B (8.4 ± 2.2) mg/caps or84.4% declared
(20.5 ± 0.1) mg/caps or
102.7% declared
C (6.9 ± 2.6) mg/caps or68.7% declared
(18.5 ± 0.1) mg/caps or
92.5% declared
D (11.2 ± 0.1) mg/caps or111.5% declared
(11.2 ± 4.3) mg/caps or
56.0% declared
E (11.0 ± 0.2) mg/caps or109.6% declared
(16.9 ±1.2) mg/caps or
84.7% do declared
Table 4. Final content of Omeprazole and Enalapril Maleate
d. Uniformity of the dosage unit
All Omeprazole samples were considered unsatisfactory for uniformity of the dosage unit.
Three samples were satisfactory for Enalapril Maleate. The results for uniformity of dosage
unit are described in Table 7 as contained in the final analysis report issued by FUNED. Var‐
iations in dose uniformity should not exceed 15% [28].
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e. Mass Variation
The acceptable limit for the analysis of variation in mass of capsules, weighing less than 300
mg is ± 10% above the average mass, and it is tolerable no more than two units outside the
specified limit and any unit may be above or below twice the percentages indicated. Thus,
only a sample of Omeprazole was considered unsatisfactory. The results for the samples of
Omeprazole and Enalapril Maleate are presented in Tables 8 and 9, respectively [27].
Pharmacy Omeprazole (10 mg/caps) Enalapril Maleate(20 mg/caps)
A 18.7% 7.8%
B 24.0% 14.2%
C 47.9% 10.6%
D 15.6% 14.0%
E 15.8% 46.5%
Table 5. Dose uniformity of the capsules of Omeprazole and Enalapril Maleate
Pharmacy average weight (mg/caps.) Lower Higher
*A 220.4 ± 1.2 2.4 1.6
B 226.8 ± 5.8 9.5 8.7
C 210.0 ± 4.9 9.7 7.5
*D 119.0 ± 2.1 6.5 10.9
**E 120.7 ± 2.9 10.9 7.9
*One unit above the limit. ** Two units above the limit. Caps, capsules
Table 6. Variation (%) in mass of the capsules of Enalapril Maleate (20 mg/caps)
Pharmacy average mass (mg/caps.) Lower Higher
*A 108.3 ± 3.0 7.1 15.1
B 195.4 ± 1.8 4.6 3.0
C 175.9 ± 3.0 9.1 4.7
**D 107.0 ± 7.0 15.3 40.8
***E 105.0 ± 2.1 10.6 7.2
*Two units above the limit. ** Four units above the limit. Unsatisfactory. *** One unit above the limit.
Table 7. Variation (%) in mass of the capsules of Enalapril Maleate (20 mg/caps)
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From the ten samples analyzed, seven were rated as unsatisfactory, considering the analysis
of aspect, mass variation, identification, related substances, uniformity of dosage units, con‐
tent and labeling.
It was observed that, if only the official established procedures (description, appearance, or‐
ganoleptic characteristics and average mass) were considered from the seven samples rated
as unsatisfactory, just one would be classified in this status. The remaining six samples
would erroneously be rated satisfactory, meaning that would be approved for human con‐
sumption [18].
Some factors may cause deviations, inherent to the handling process of drugs in capsules,
such as the loss of substance during the grinding, mixing and filling the capsules. Miscalcu‐
lations and weight of the formulation components, errors inherent to the operator and the
use of damaged equipment may also compromise the process and therefore the quality of
the final product [29].
The results of Omerazole and Enalapril Maleate were analyzed by ANOVA followed by Tu‐
key's test for uniformity of content and unit dose. Results were considered significantly dif‐
ferent at p < 0.05.
3.2. Neutron activation analysis
3.2.1. Material and methods
All samples of Omeprazole and Enalapril Maleate were purchased in the market of the Belo
Horizonte, state of Minas Gerais, Brazil from five (5) different magistral pharmacies.
Due to operational reasons, Jožef Stefan Institute (JSI) performed analyses only from three
(3) different pharmacies from the sampling group. Due to same operational reasons, the JSI
did not analyze the short half-lives radionuclides of elements like Al, Cl, Mg, Mn and Ti.
The samples of Omeprazole and Enalapril Maleate performed by the JSI were packed in
polyethylene capsules in plastic bottle containing 20 capsules each. Whole powder mass
from 20 capsules was taken to prepare homogenized samples, which was transferred in
clean polyethylene bottle. In the samples of Omeprazole performed by CDTN, just one the
mass of one capsule taken randomly was considered by each sample. The difference of pro‐
cedures carried out by both Institutes was due to operational reasons.
Both institutes CDTN/CNEN and JSI followed the same procedure to prepare the samples.
The aliquots of each sample were manually crushed or ground using an agate mortar with
pestle, whenever necessary, to avoid any contamination. In most cases, unless the amount of
material did not allow it, two replicates were taken and weighed in polyethylene vials. It is
relevant to emphasize that no additional chemical sample preparation was performed. At
CDTN/CNEN and IJS, the samples were irradiated together with several Al–0.1% Au disks
as neutron flux monitors, according to the k0-standardisation method procedure [23,24,30].
Table 10 shows the characteristics of the applied technique such as the parameters f (thermal
to epithermal fluxes ratio) and the α (parameter which measures the epithermal flux devia‐
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tion from the ideal (1/E) distribution), needed for the k0-method, the irradiation times and
gamma spectrometry systems at each Institute.
3.2.2. Results and discussion
The obtained results of NAA from the medicines Omeprazole and Enalapril Maleate are
showed in the Tables 11 to 13.
The technique applied was suitable for determining 20 chemical elements – Al, Br, Ca, Cl,
Co, Cr, Fe, Mg, Mn, Na, Sb, Sc, Sm, Sr, Ta, Th, Ti, U and Zn – in a large range of concentra‐
tion, without any chemical process. The elements Cl, Fe, K, Mg, Mn, Na, and Zn could be
expected in this kind of samples. Other elements, not considered essential, for the human
being such as As and Sr, found in lower concentration compared to Cl, Fe, K, Mg, Mn, Na,
and Zn can also represent a health problem in a long term consumption. Even essential ele‐
ments were determined but in high concentrations, like Fe may be toxic.
High concentration of elements such as Cl, Ca, Mg, Na and Ti are expected because they are
frequently components of excipients in the preparation of pellets. The presence of Mg is due
to the excipients usually used: magnesium is a component of magnesium estearate
(Mg[C18H35O2]), a lubricant for tablets and capsules and opadry, coloring agent, respectively
[26]. Mg also is present in magnesium silicate (Mg3SiO4(OH)2] Na is a component of sodium
laurilsulfate, ([CH3(CH2)10(CH2O)(SO3)Na] and sodium bicarbonate NaHCO3. Ca is added as
excipient as calcium phosphate and Ti as titanium dioxide, TiO2. Fe comes from red iron ox‐
ide, used as excipient as well [10,13]. The impurities such as Br, Co, Cr, Hf, La, Sb, Sc, Sm, Sr,
Ta, Th and U, are probably original from the raw material and/or from the process of pro‐
duction and manipulation of the medicine. All elements determined not foreseen in the orig‐
inal formula can be considered as impurities.
INSTITUTE
CDTN/CNEN JSI
Thermal Flux
(neutrons cm-2 s-1)
6.4x 1011 1.1x 1012
k0-standardisation parameters
f
α
20.4
0.197
28.6
- 0.011
Irradiation time (h) 8 13
Detector nominal efficiency (%) 50 40
Software used for:
Acquisition spectra
Spectra Analysis
Concentration calculation
Genie 2000
(CANBERRA)
HyperLab
Kayzero for Windows, V.2.42
Genie 2000
(CANBERRA)
HyperLab
Kayzero for Windows, V.2.42
Sample mass (mg) 200-250 240-250
Table 8. Experimental information of neutron activation analysis
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The data presented in Tables 12, 13 and 14 cannot be compared directly because the samples
analyzed are not from the batch, but the results are, in general, very similar. Most results
determined by the CDTN in one capsule of Omeprazole taken randomly were also deter‐
mined by the JSI in the homogenized samples, except for the elements Br, Cr and La. The
concentrations of the elements determined by both institutes have, in general, the same
magnitude.
The discussion about toxicity levels and possible consequences for humans being is very dif‐
ficult, due to the low concentration of the elements and limitations on the studies available
in the literature. For most trace elements, there are just some available data on acute and
chronic toxicity in experimental animals, not sufficient data to assess the risks to the human
health on a long term daily intake [22].
4. Conclusion
The obtained results of samples of omeprazole and enalapril from five different magistral
pharmacies of Belo Horizonte, Brazil, confirm the concern about the quality and safety for
consumption of formulated medicines. They represent a preliminary part of a more com‐
plete investigation, still under way.
From the ten samples analyzed, seven were considered unsatisfactory. Most of the problems
found through analyses Omeprazole and Enalapril Maleate medicines, like the variation of
active principle mass, mass variation and dosage unit, come from the inadequacy of proce‐
dures for handling the ingredients in the pharmacy.
Problems can also be caused by the quality of the raw material used and inefficient or inexis‐
tence of test for checking the material. Diversified impurities reinforce the hypothesis that
these elements are not controlled by the quality system. It also suggests that quality control
over the purity of medicines in general should be established, as well as the concentration
limits for the impurities, at least for some elements like As, Cd, Cu, Hg, Pb and Sn, already
foreseen for food in the Brazilian legislation.
The possible harmful and/or toxicological effects for the human health as a consequence of
long term use of the formulated medicines represent an important concern for the authori‐
ties of the public health system. Recent cases of contamination and death in Brazil due to the
consumption of inadequate formulated medicines has been enhancing the debate about the
quality of the magistral pharmacy.
In conclusion, the results point out the necessity of prompt and efficient actions by the au‐
thorities of the health public system to assure the quality of formulated medicines. The aim
of this work is just to provide evidences in order to contribute with this initiative.
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Pharmacy
Element A B C D E
Al 532 ± 20 260 ± 10 305 ± 11 452 ± 17 335 ± 12
Br DL 0.60 ± 0.03 DL DL DL
Ca 17740 ± 793 9379 ± 446 11230 ± 512 19600 ± 880 14260 ± 190
Cl 806 ± 48 313 ± 18 262 ± 18 490 ± 30 514 ± 31
Co 0.5 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 DL ± 0.10 ± 0.01
Cr 11.7 ± 0.5 7.9 ± 0.3 6.7 ± 0.3 11.6 ± 0.5 13 ± 1
Fe 65 ± 5 64 ± 11 47 ± 10 49 ± 11 51 ± 5
Mg 4643 ± 192 449 ± 28 390 ± 28 998 ± 57 697 ± 47
Mn 2.8 ± 0.3 1.4 ± 0.1 DL 1.8 0.2 2.2 0.2
Na 8134 ± 326 4003 ± 144 3918 ± 140 6838 ± 241 6718 ± 247
Sb 0.09 ± 0.01 0.41 ± 0.02 0.04 ± 0.01 0.06 ± 0.01 0.13 ± 0.01
Table 9. Elemental concentration (mg.kg-1) for Omeprazole (CDTN/CNEN)
Pharmacy
Element A B C D E
Sc 0.03 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01
Sm DL 0.02 ± DL 0.02 0.01 DL
Sr DL DL DL 21 ± 4 DL
Ta 0.02 ± 0.01 0.14 ± 0.01 DL 0.15 ± 0.01 0.09 ± 0.01
Ti 2748 ± 105 1483 ± 55 897 ± 34 2124 ± 79 1907 ± 71
U DL 0.22 ± 0.01 DL DL 0.4 ± 0.1
Zn 3.4 ± 0.4 1.8 ± 0.3 DL 2.9 ± 0.4 2.5 ± 0.3
* DL – Lower than the Detection Limit
Table 10. Elemental concentration (mg.kg-1) for Omeprazole (CDTN/CNEN)
Pharmacy
Element A B C
Br 0.19 ± 0.01 0.17 ± 0.01 0.22 ± 0.01
Ca 16453 ± 592 14908 ± 540 12817 ± 467
Ce DL DL ± 0.09 ± 0.01
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Pharmacy
Element A B C
Co 0.18 ± 0.01 0.016 ± 0.001 0.51 ± 0.02
Cr 0.52 ± 0.03 0.26 ± 0.02 0.59 ± 0.04
Fe 102 ± 4 53 ± 2 265 ± 9
Hf 0.020 ± 0.001 0.009 ± 0.001 0.021 ± 0.002
La 0.019 ± 0.002 0.030 ± 0.004 0.040 ± 0.002
Mo 0.34 ± 0.05 DL ± DL
Na 6616 ± 232 5988 ± 210 4836 ± 169
Sb 0.014 ± 0.001 0.012 ± 0.001 0.011 ± 0.001
Sc 0.013 ± 0.005 0.010 ± 0.001 0.022 ± 0.001
Sm DL DL 0.0052 ± 0.0003
Sr 22.3 ± 1.1 17.4 ± 1.0 9.0 ± 1.0
Ta 0.34 ± 0.01 0.076 ± 0.003 0.42 ± 0.02
Th 0.012 ± 0.002 DL 0.027 ± 0.002
U 0.09 ± 0.01 0.14 ± 0.01 0.053 ± 0.004
Zn 0.60 ± 0.1 0.4 ± 0.1 0.7 ± 0.1
* DL – Lower than the Detection Limit
Table 11. Elemental concentration (mg.kg-1) for Omeprazole (JSI)
Pharmacy
Element A B C
Br 0.13 ± 0.01 0.47 ± 0.02 0.24 ± 0.02
Cr 0.07 ± 0.01 0.15 ± 0.01 0.10 ± 0.01
Na 12540 ± 439 271 ± 10 72480 ± 2538
Sc 0.0009 ± 0.0001 0.0007 ± 0.0001 0.0054 ± 0.0002
Sb 0.09 ± 0.01 0.41 ± 0.02 0.04 ± 0.01
Th DL DL 0.015 ± 0.001
Zn 0.49 ± 0.04 DL 0.015 ± 0.001
* DL – Lower than the Detection Limit
Table 12. Elemental concentration (mg.kg-1) for Enalapril Maleate (JSI)
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